Berlin – South Korean pharmaceutical firm Yuyu Pharma’s Bemfola Prefilled Pen (polytropin alfa), a fertility treatment, is facing increased scrutiny following reports of previously unreported side effects, including ovarian hyperstimulation syndrome (OHSS) and syncope (fainting). The South Korean Ministry of Food and Drug Safety (MFDS) is currently reviewing data from a domestic post-market surveillance study to update the drug’s labeling and usage guidelines, according to a report from News The Voice Healthcare.
The review stems from a four-year post-market surveillance study involving 618 patients. The study revealed an overall adverse event rate of 9.22% (57 out of 618 patients, representing 70 events). While not all events were determined to be directly related to Bemfola, the findings prompted the MFDS to consider adding newly identified risks to the drug’s official information.
Ovarian Hyperstimulation Syndrome and Other Reported Adverse Effects
Ovarian hyperstimulation syndrome (OHSS) is a potentially serious complication of fertility treatments that involve ovarian stimulation. According to Seoul National University Hospital, OHSS occurs when the ovaries develop into overstimulated, leading to fluid accumulation and other complications. The study identified cases of OHSS and pelvic hematoma among patients treated with Bemfola. The MFDS is likewise considering adding reports of skin reactions – including urticaria (hives), blisters, and pruritus (itching) – and neurological effects, specifically syncope, to the drug’s list of potential side effects.
The reported adverse reactions are categorized as “uncommon,” occurring in between 0.1% and 1% of patients. Serious adverse reactions, where a causal relationship could not be ruled out, were observed in 0.32% of patients (2 out of 618, representing 2 events). Unexpected adverse reactions were reported in 0.81% of patients (5 out of 618, representing 6 events).
Bemfola Prefilled Pen: What Patients Demand to Grasp
Bemfola Prefilled Pen contains follitropin alfa, a type of follicle-stimulating hormone (FSH) used to stimulate the development of follicles in the ovaries, a crucial step in assisted reproductive technologies like in vitro fertilization (IVF). Information from the Health Korea database indicates that, in cases of OHSS, the administration of human chorionic gonadotropin (hCG) should be suspended. Patients are also advised to abstain from sexual intercourse or use contraception for at least four days.
The drug is administered via subcutaneous injection. The standard presentation is a pre-filled pen containing 0.125mL of the solution. It’s critical for patients to understand the potential risks and benefits of Bemfola, and to discuss any concerns with their healthcare provider.
Understanding Ovarian Hyperstimulation Syndrome
OHSS can range in severity from mild discomfort to a life-threatening medical emergency. Symptoms can include abdominal bloating, abdominal pain, weight gain, nausea, vomiting, decreased urination, and difficulty breathing. Severe cases may require hospitalization and fluid drainage. Risk factors for OHSS include young age, low body weight, polycystic ovary syndrome (PCOS), and the use of high doses of FSH.
Regulatory Review and Next Steps
The MFDS is currently seeking feedback on the proposed changes to Bemfola’s labeling. Stakeholders have until March 8, 2026, to submit comments and supporting documentation to the Bio-Pharmaceutical Quality Control Division of the MFDS. The agency will then review the feedback and make a final decision regarding the updates to the drug’s prescribing information.
This review highlights the importance of ongoing post-market surveillance for pharmaceutical products. By continuously monitoring the safety and efficacy of drugs after they are released to the market, regulatory agencies can identify and address potential risks, ensuring patient safety. The MFDS’s proactive approach in reviewing the Bemfola data demonstrates a commitment to protecting public health.
Key Takeaways
- Bemfola Prefilled Pen, a fertility drug, is under review by the South Korean MFDS due to newly reported side effects.
- The reported side effects include ovarian hyperstimulation syndrome (OHSS) and syncope.
- The review is based on a post-market surveillance study involving 618 patients.
- Patients should discuss the potential risks and benefits of Bemfola with their healthcare provider.
- The MFDS is seeking feedback on proposed labeling changes until March 8, 2026.
The MFDS’s decision on the proposed labeling changes is expected in the coming weeks. Patients and healthcare professionals are encouraged to stay informed about updates from the MFDS regarding Bemfola Prefilled Pen. Further information can be obtained directly from the MFDS website or through consultation with a qualified healthcare provider.
Do you have experience with fertility treatments or Bemfola? Share your thoughts and questions in the comments below. Please also share this article with anyone who may find this information helpful.
Worth a look